补体蛋白调节特异性抗体的作用，有助于处理和去除免疫复合物，并调节 T 细胞和 B 细胞反应。
可疑的表现包括 5 岁以上个体患流行性脑脊髓膜炎、复发性细菌感染、无荨麻疹的血管性水肿、肾脏和眼系统出现炎性疾病以及自身免疫性临床表现。
Michael Kirschfink, DVM, PhD
Professor of Immunology
German Society of Immunology
Institute of Immunology
University of Heidelberg
MK has sat on Roche and Euro Diagnostica advisory boards; presented a lecture for Novartis; and acted as a consultant for Back Bay Life Science Advisors, Ionis Pharmaceuticals, Fresenius Care Germany, and Ablynx. MK is a author of references in this topic.
Professor Michael Kirschfink would like to gratefully acknowledge Dr D. J. Unsworth, a previous contributor to this topic.
DJU owns shares in Glaxo and Shire, and has had registration fees paid for CPD attendance at international conferences by ALK Alkabelo (2015 - EACCI - Allergy) and CSL - Bearing (2016 - ESID - Immunodeficiency).
Charles Kirkpatrick, MD (UCHSC)
Professor of Medicine
Adult Immunodeficiency Program
University of Colorado Denver
CK is an author of a reference cited in this monograph. CK has received speaker fees from Cention, Aventis Behring, and Bristol Myers Squibb. CK has received honorarium for speaking at the Aspen Allergy Conference, for the Colorado Allergy Society. CK ran the research program for a biotechnology company with an approximate budget of $3.5 million.